LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.63 1.87

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.56

Max

1.6400000000000001

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+158.33% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	158M 652M
Eelmine avamishind	-0.24
Eelmine sulgemishind	1.63

Uudiste sentiment

By Acuity

50%

158 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. märts 2026, 18:43 UTC

Uudisväärsed sündmused

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3. märts 2026, 17:33 UTC

Omandamised, ülevõtmised, äriostud

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3. märts 2026, 23:45 UTC

Market Talk

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3. märts 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3. märts 2026, 23:25 UTC

Market Talk

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3. märts 2026, 23:25 UTC

Market Talk

Global Energy Roundup: Market Talk

3. märts 2026, 22:38 UTC

Uudisväärsed sündmused

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3. märts 2026, 22:16 UTC

Tulu

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3. märts 2026, 22:09 UTC

Tulu

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3. märts 2026, 22:06 UTC

Tulu

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3. märts 2026, 22:05 UTC

Tulu

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3. märts 2026, 22:03 UTC

Tulu

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Tech, Media & Telecom Roundup: Market Talk

3. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

3. märts 2026, 21:45 UTC

Uudisväärsed sündmused

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3. märts 2026, 21:37 UTC

Tulu

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3. märts 2026, 21:26 UTC

Uudisväärsed sündmused

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3. märts 2026, 20:31 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3. märts 2026, 20:04 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3. märts 2026, 19:17 UTC

Market Talk

Uudisväärsed sündmused

Gold and Silver Drop as Energy Surges -- Market Talk

3. märts 2026, 18:43 UTC

Tulu

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3. märts 2026, 18:29 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

3. märts 2026, 18:29 UTC

Market Talk

Uudisväärsed sündmused

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3. märts 2026, 18:22 UTC

Uudisväärsed sündmused

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3. märts 2026, 18:22 UTC

Uudisväärsed sündmused

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3. märts 2026, 18:17 UTC

Market Talk

Uudisväärsed sündmused

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3. märts 2026, 18:14 UTC

Tulu

How Long Can Anthropic Play Defense? -- WSJ

3. märts 2026, 17:41 UTC

Uudisväärsed sündmused

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3. märts 2026, 17:36 UTC

Uudisväärsed sündmused

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3. märts 2026, 17:28 UTC

Omandamised, ülevõtmised, äriostud

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

158.33% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 158.33%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

158 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.